153203-80-6

Usage

Uses

Used in Pharmaceutical Synthesis:
3,5-dichloro-4-formylbenzoic acid is used as an intermediate in the production of various drugs. Its unique structure allows for the synthesis of a wide range of pharmaceutical compounds, making it a valuable asset in the development of new medications.
Used in Agrochemical Production:
In the agrochemical industry, 3,5-dichloro-4-formylbenzoic acid is utilized as a building block for the synthesis of various agrochemicals. Its properties enable the creation of effective compounds for pest control and crop protection.
Used in Dye and Perfume Manufacturing:
3,5-dichloro-4-formylbenzoic acid is also employed in the production of dyes and perfumes. Its chemical structure allows for the development of a variety of colorants and fragrances, contributing to the diversity of products in these industries.
Used in Biological Research:
3,5-dichloro-4-formylbenzoic acid has been studied for its potential biological activities, including anti-inflammatory and cytotoxic properties. This research is crucial for understanding its potential applications in medicine and other fields, as well as for discovering new therapeutic agents.

Upstream product

• 4394-85-8 4-morpholinecarboxaldehyde 
• 51-36-5 3,5-dichlorobenzoic acid 
• 761-65-9 N,N-dibutylformamide 
• 68-12-2 N,N-dimethyl-formamide 
• 153203-78-2 4-bromomethyl-3,5-dichlorobenzoic acid 

Downstream Products

• 153203-81-7 4-formyl-3,5-dichlorobenzoyl chloride 
• 1110767-89-9 3,5-dichloro-4-[(1E)-3-ethoxy-2-methyl-3-oxoprop-1-en-1-yl]benzoic acid 
• 1465326-89-9 methyl 3,5-dichloro-4-formylbenzoate 
• 802616-47-3 2,6-dichloro-4-(methoxycarbonyl)benzoic acid 

Relevant academic research and scientific papers

Development of manufacturing processes for the carboxylic acid key intermediate of lusutrombopag: One-pot reaction process of formylation and the horner-wadsworth-emmons reaction

We describe the development of a one-pot preparation process of (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop- 1-en-1-yl)benzoic acid (3), which is a key carboxylic acid intermediate of lusutrombopag. This one-pot reaction process is composed of lithiation of 3,5-dichlorobenzoic acid with lithium diisopropylamide (LDA), formylation using N-formylmorpholine, followed by olefination employing the Horner-Wadsworth-Emmons reaction with triethyl 2-phosphonopropionate. This method enabled kilogram-scale manufacturing of carboxylic acid 3, a key intermediate of lusutrombopag with high purity, together with a reduced number of steps, improvement of yield, and avoidance of a cumbersome procedure for isolation of the intermediate.

Preparation method for intermediates of new medicine Lusutrombopag resisting to thrombopenia

The invention discloses a preparation method for intermediates of a new medicine Lusutrombopag resisting to thrombopenia. According to the invention, column chromatography of each step is avoided through an effective method with regard to preparation for an intermediate I, and in addition, bromo-compounds are used for replacing chloro-compounds in the step of ring closure, thus the ring closure has a quantitative yield and is quite easy to operate. In addition, the second carbonyl group and bromine are introduced stepwise, thus the two steps achieve a yield of more than 80%, and are stable and easy to repeat. Compared with the yield of 25-30% of the last two steps of the original research document, the yield is greatly increased, and the preparation method is simple and convenient to operate, and easy to repeat. According to the invention, synthesis for an intermediate II is realized with a quite high yield (70-80%) and an extremely short route through two effective strategies with regard to the intermediate II.

A kind of the second aryl amine derivative and its preparation method, pharmaceutical composition and use thereof

The invention provides diarylamide type derivatives having a structure shown as a formula (I) as follows, or pharmaceutically acceptable salts thereof, a preparing method of the derivatives, compositions containing the derivatives and the pharmaceutically acceptable salts, and medicine uses of the derivatives and the pharmaceutically acceptable salts. The diarylamide type derivatives having the structure shown as the formula (I) or the pharmaceutically acceptable salts thereof have antagonistic effects on FXR. Integral animal experiments show that the compounds have effects of decreasing blood sugar and reducing blood fat. The compounds can be used for treating hyperlipidemia and type 2 diabetes mellitus.